LUME-Colon 1: A double-blind, randomized phase III study of nintedanib plus best supportive care (BSC) versus placebo plus BSC in patients with colorectal cancer (CRC) refractory to standard therapies.
2015 ◽
Vol 33
(15_suppl)
◽
pp. TPS3625-TPS3625
◽
Keyword(s):
Keyword(s):
Keyword(s):
2016 ◽
Vol 15
(1)
◽
pp. 91-94.e1
◽
Keyword(s):
2017 ◽
Vol 24
(2)
◽
pp. 316-325
◽
Keyword(s):
2009 ◽
Vol 27
(18S)
◽
pp. CRA8000-CRA8000
◽
Keyword(s):
2010 ◽
Vol 28
(15_suppl)
◽
pp. 7506-7506
◽
Keyword(s):